Neng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Neng Wang has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Zhiyu Wang
State Key Laboratory of Traditional Chinese Medicine Syndrome, Chinese Medicine Guangdong Laboratory, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
5 shared publications Bowen Yang
Integrative Research Laboratory of Breast Cancer, the Research Center for Integrative Cancer Medicine, Discipline of Integrated Chinese and Western Medicine & the Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510006, China
4 shared publicationsShengqi Wang
Integrative Research Laboratory of Breast Cancer, the Research Center for Integrative Cancer Medicine, Discipline of Integrated Chinese and Western Medicine & the Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510006, China
4 shared publicationsFengxue Zhang
Integrative Research Laboratory of Breast Cancer, the Research Center for Integrative Cancer Medicine, Discipline of Integrated Chinese and Western Medicine & the Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510006, China
3 shared publicationsYifeng Zheng
Integrative Research Laboratory of Breast Cancer, the Research Center for Integrative Cancer Medicine, Discipline of Integrated Chinese and Western Medicine & the Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510006, China
3 shared publicationsJuxian Song
School of Chinese Medicine, Hong Kong Baptist University, 999077, Kowloon Tong, Hong Kong
2 shared publications
Latest Publications
- 29 September 2026
- Published by Elsevier in Phytomedicine
- Vol. 162
Qishen granule improves myocardial fibrosis in heart failure via Piezo1/Calpain2/LAMP1/CTSS in CCR2+ macrophages
- 29 September 2026
- Published by Elsevier in Phytomedicine
- Vol. 162
Qishen granule improves myocardial fibrosis in heart failure via Piezo1/Calpain2/LAMP1/CTSS in CCR2+ macrophages
- 24 September 2025
- Published by Elsevier in Phytomedicine
- Vol. 148, 157304
The chemosensitizing activity of betulinic acid in suppressing macrophage polarization through GSK-3β/β-catenin/CXCL1 signaling in breast cancer
- 24 September 2025
- Published by Elsevier in Phytomedicine
- Vol. 148, 157304
The chemosensitizing activity of betulinic acid in suppressing macrophage polarization through GSK-3β/β-catenin/CXCL1 signaling in breast cancer
- 15 June 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 121, 110489
The value of NLR versus MLR in the short-term prognostic assessment of HBV-related acute-on-chronic liver failure
- 15 June 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 121, 110489
The value of NLR versus MLR in the short-term prognostic assessment of HBV-related acute-on-chronic liver failure
- 21 May 2021
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 84 (6) , 1838-1842
Iron-Catalyzed Skeletal Conversion of Lathyrane to Premyrsinane Euphorbia Diterpenes and Their Cytotoxic Activities
Two new premyrsinane-type diterpenes (2 and 3) as diastereomers were synthesized from lathyrane-type diterpene euphorbia factor L3 (1) for the first time via an efficient Fe(acac)3-catalyzed skeleton conversion process. This conversion features a biogenetically inspired strategy that relies on a concise reductive olefin coupling involving intramolecular Michael addition with free radicals. The structures of 2 and 3 were elucidated by a combination of the interpretation of their spectroscopic data and single-crystal X-ray diffraction analysis. The premyrsinane diterpenes 2 and 3 exhibited cytotoxic activity against the 4T1 breast cancer cell line, while the parent compound euphorbia factor L3 (1) was inactive. The current results not only confirmed the biogenetic relationship between lathyranes and premyrsinanes for the first time but also suggested a novel method for the preparation of naturally rare premyrsinane diterpenes with high bioactivity from the more abundant natural lathyrane diterpenes.
- 21 May 2021
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 84 (6) , 1838-1842
Iron-Catalyzed Skeletal Conversion of Lathyrane to Premyrsinane Euphorbia Diterpenes and Their Cytotoxic Activities
Two new premyrsinane-type diterpenes (2 and 3) as diastereomers were synthesized from lathyrane-type diterpene euphorbia factor L3 (1) for the first time via an efficient Fe(acac)3-catalyzed skeleton conversion process. This conversion features a biogenetically inspired strategy that relies on a concise reductive olefin coupling involving intramolecular Michael addition with free radicals. The structures of 2 and 3 were elucidated by a combination of the interpretation of their spectroscopic data and single-crystal X-ray diffraction analysis. The premyrsinane diterpenes 2 and 3 exhibited cytotoxic activity against the 4T1 breast cancer cell line, while the parent compound euphorbia factor L3 (1) was inactive. The current results not only confirmed the biogenetic relationship between lathyranes and premyrsinanes for the first time but also suggested a novel method for the preparation of naturally rare premyrsinane diterpenes with high bioactivity from the more abundant natural lathyrane diterpenes.
- Open Access
- 28 December 2020
- Published by Wolters Kluwer Health in Chinese Medicine and Culture
- Vol. 3 (4) , 245-253
Research Advances of Traditional Chinese Medicine in Cancer Immunotherapy
Tumorigenesis are closely associated with the immune function of the human body. Immunotherapy has emerged as a novel and promising treatment strategy in multiple malignancies in the 21st century. Traditional Chinese medicine (TCM) has been extensively used for cancer treatment in China and surrounding countries for it exerts efficient therapeutic effects with few side effects. In recent years, studies have demonstrated that TCM plays a unique and reliable role in regulating tumor immunity. TCM can enhance the antitumor immune response function by regulating the secretion of cytokines, reshaping the balance of immune cells, and regulating immune checkpoints to relieve the immunosuppression. In addition, TCM can reduce the side effects (e.g., cytokine storm) of cancer immunotherapy. Based on the current research of active immunotherapy and passive immunotherapy, this review summarizes the potential applications and existing problems of TCM in tumor immunotherapy. This review may be helpful in illuminating the scientific basis of TCM in tumor immunotherapy, promoting its internationalization, as well as shedding innovating new strategies for the development of tumor immunotherapy.
- 28 December 2020
- Published by Wolters Kluwer Health in Chinese Medicine and Culture
- Vol. 3 (4) , 245-253
Open AccessResearch Advances of Traditional Chinese Medicine in Cancer Immunotherapy
Tumorigenesis are closely associated with the immune function of the human body. Immunotherapy has emerged as a novel and promising treatment strategy in multiple malignancies in the 21st century. Traditional Chinese medicine (TCM) has been extensively used for cancer treatment in China and surrounding countries for it exerts efficient therapeutic effects with few side effects. In recent years, studies have demonstrated that TCM plays a unique and reliable role in regulating tumor immunity. TCM can enhance the antitumor immune response function by regulating the secretion of cytokines, reshaping the balance of immune cells, and regulating immune checkpoints to relieve the immunosuppression. In addition, TCM can reduce the side effects (e.g., cytokine storm) of cancer immunotherapy. Based on the current research of active immunotherapy and passive immunotherapy, this review summarizes the potential applications and existing problems of TCM in tumor immunotherapy. This review may be helpful in illuminating the scientific basis of TCM in tumor immunotherapy, promoting its internationalization, as well as shedding innovating new strategies for the development of tumor immunotherapy.
- Open Access
- 11 June 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (6) , 1-16
Caveolin-1 inhibits breast cancer stem cells via c-Myc-mediated metabolic reprogramming
Breast cancer stem cells (BCSCs) are considered to be the root of breast cancer occurrence and progression. However, the characteristics and regulatory mechanisms of BCSCs metabolism have been poorly revealed, which hinders the development of metabolism-targeted treatment strategies for BCSCs elimination. Herein, we demonstrated that the downregulation of Caveolin-1 (Cav-1) usually occurred in BCSCs and was associated with a metabolic switch from mitochondrial respiration to aerobic glycolysis. Meanwhile, Cav-1 could inhibit the self-renewal capacity and aerobic glycolysis activity of BCSCs. Furthermore, Cav-1 loss was associated with accelerated mammary-ductal hyperplasia and mammary-tumor formation in transgenic mice, which was accompanied by enrichment and enhanced aerobic glycolysis activity of BCSCs. Mechanistically, Cav-1 could promote Von Hippel-Lindau (VHL)-mediated ubiquitination and degradation of c-Myc in BCSCs through the proteasome pathway. Notably, epithelial Cav-1 expression significantly correlated with a better overall survival and delayed onset age of breast cancer patients. Together, our work uncovers the characteristics and regulatory mechanisms of BCSCs metabolism and highlights Cav-1-targeted treatments as a promising strategy for BCSCs elimination.
- 11 June 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (6) , 1-16
Open AccessCaveolin-1 inhibits breast cancer stem cells via c-Myc-mediated metabolic reprogramming
Breast cancer stem cells (BCSCs) are considered to be the root of breast cancer occurrence and progression. However, the characteristics and regulatory mechanisms of BCSCs metabolism have been poorly revealed, which hinders the development of metabolism-targeted treatment strategies for BCSCs elimination. Herein, we demonstrated that the downregulation of Caveolin-1 (Cav-1) usually occurred in BCSCs and was associated with a metabolic switch from mitochondrial respiration to aerobic glycolysis. Meanwhile, Cav-1 could inhibit the self-renewal capacity and aerobic glycolysis activity of BCSCs. Furthermore, Cav-1 loss was associated with accelerated mammary-ductal hyperplasia and mammary-tumor formation in transgenic mice, which was accompanied by enrichment and enhanced aerobic glycolysis activity of BCSCs. Mechanistically, Cav-1 could promote Von Hippel-Lindau (VHL)-mediated ubiquitination and degradation of c-Myc in BCSCs through the proteasome pathway. Notably, epithelial Cav-1 expression significantly correlated with a better overall survival and delayed onset age of breast cancer patients. Together, our work uncovers the characteristics and regulatory mechanisms of BCSCs metabolism and highlights Cav-1-targeted treatments as a promising strategy for BCSCs elimination.
- Top Cited PapersOpen Access
- 16 April 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (4) , 1-20
CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling
Prostate cancer stem cells (PCSCs) play a critical role in prostate cancer progression and metastasis, which remains an obstacle for successful prostate cancer treatment. Tumor-associated macrophages (TAMs) are the most abundant immune cell population within the tumor microenvironment (TME). Systematic investigation of the interaction and network signaling between PCSCs and TAMs may help in searching for the critical target to suppress PCSCs and metastasis. Herein, we demonstrated that TAMs-secreted CCL5 could significantly promote the migration, invasion, epithelial–mesenchymal transition (EMT) of prostate cancer cells as well as the self-renewal of PCSCs in vitro. QPCR screening validated STAT3 as the most significant response gene in prostate cancer cells following CCL5 treatment. RNA-sequencing and mechanistic explorations further revealed that CCL5 could promote PCSCs self-renewal and prostate cancer metastasis via activating the β-catenin/STAT3 signaling. Notably, CCL5 knockdown in TAMs not only significantly suppressed prostate cancer xenografts growth and bone metastasis but also inhibited the self-renewal and tumorigenicity of PCSCs in vivo. Finally, clinical investigations and bioinformatic analysis suggested that high CCL5 expression was significantly correlated with high Gleason grade, poor prognosis, metastasis as well as increased PCSCs activity in prostate cancer patients. Taken together, TAMs/CCL5 could promote PCSCs self-renewal and prostate cancer metastasis via activating β-catenin/STAT3 signaling. This study provides a novel rationale for developing TAMs/CCL5 as a potential molecular target for PCSCs elimination and metastatic prostate cancer prevention.
- 16 April 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (4) , 1-20
Top Cited PapersOpen AccessCCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling
Prostate cancer stem cells (PCSCs) play a critical role in prostate cancer progression and metastasis, which remains an obstacle for successful prostate cancer treatment. Tumor-associated macrophages (TAMs) are the most abundant immune cell population within the tumor microenvironment (TME). Systematic investigation of the interaction and network signaling between PCSCs and TAMs may help in searching for the critical target to suppress PCSCs and metastasis. Herein, we demonstrated that TAMs-secreted CCL5 could significantly promote the migration, invasion, epithelial–mesenchymal transition (EMT) of prostate cancer cells as well as the self-renewal of PCSCs in vitro. QPCR screening validated STAT3 as the most significant response gene in prostate cancer cells following CCL5 treatment. RNA-sequencing and mechanistic explorations further revealed that CCL5 could promote PCSCs self-renewal and prostate cancer metastasis via activating the β-catenin/STAT3 signaling. Notably, CCL5 knockdown in TAMs not only significantly suppressed prostate cancer xenografts growth and bone metastasis but also inhibited the self-renewal and tumorigenicity of PCSCs in vivo. Finally, clinical investigations and bioinformatic analysis suggested that high CCL5 expression was significantly correlated with high Gleason grade, poor prognosis, metastasis as well as increased PCSCs activity in prostate cancer patients. Taken together, TAMs/CCL5 could promote PCSCs self-renewal and prostate cancer metastasis via activating β-catenin/STAT3 signaling. This study provides a novel rationale for developing TAMs/CCL5 as a potential molecular target for PCSCs elimination and metastatic prostate cancer prevention.
- Open Access
- 19 August 2019
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2019, 1-15
Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway
Targeting aberrant metabolism is a promising strategy for inhibiting cancer growth and metastasis. Research is now geared towards investigating the inhibition of glycolysis for anticancer drug development. Betulinic acid (BA) has demonstrated potent anticancer activities in multiple malignancies. However, its regulatory effects on glycolysis and the underlying molecular mechanisms are still unclear. BA inhibited invasion and migration of highly aggressive breast cancer cells. Moreover, BA could suppress aerobic glycolysis of breast cancer cells presenting as a reduction of lactate production, quiescent energy phenotype transition, and downregulation of aerobic glycolysis-related proteins. In this study, glucose-regulated protein 78 (GRP78) was also identified as the molecular target of BA in inhibiting aerobic glycolysis. BA treatment led to GRP78 overexpression, and GRP78 knockdown abrogated the inhibitory effect of BA on glycolysis. Further studies demonstrated that overexpressed GRP78 activated the endoplasmic reticulum (ER) stress sensor PERK. Subsequent phosphorylation of eIF2α led to the inhibition of β-catenin expression, which resulted in the inhibition of c-Myc-mediated glycolysis. Coimmunoprecipitation assay revealed that BA interrupted the binding between GRP78 and PERK, thereby initiating the glycolysis inhibition cascade. Finally, the lung colonization model validated that BA inhibited breast cancer metastasis in vivo, as well as suppressed the expression of aerobic glycolysis-related proteins. In conclusion, our study not only provided a promising drug for aerobic glycolysis inhibition but also revealed that GRP78 is a novel molecular link between glycolytic metabolism and ER stress during tumor metastasis.
- 19 August 2019
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2019, 1-15
Open AccessBetulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway
Targeting aberrant metabolism is a promising strategy for inhibiting cancer growth and metastasis. Research is now geared towards investigating the inhibition of glycolysis for anticancer drug development. Betulinic acid (BA) has demonstrated potent anticancer activities in multiple malignancies. However, its regulatory effects on glycolysis and the underlying molecular mechanisms are still unclear. BA inhibited invasion and migration of highly aggressive breast cancer cells. Moreover, BA could suppress aerobic glycolysis of breast cancer cells presenting as a reduction of lactate production, quiescent energy phenotype transition, and downregulation of aerobic glycolysis-related proteins. In this study, glucose-regulated protein 78 (GRP78) was also identified as the molecular target of BA in inhibiting aerobic glycolysis. BA treatment led to GRP78 overexpression, and GRP78 knockdown abrogated the inhibitory effect of BA on glycolysis. Further studies demonstrated that overexpressed GRP78 activated the endoplasmic reticulum (ER) stress sensor PERK. Subsequent phosphorylation of eIF2α led to the inhibition of β-catenin expression, which resulted in the inhibition of c-Myc-mediated glycolysis. Coimmunoprecipitation assay revealed that BA interrupted the binding between GRP78 and PERK, thereby initiating the glycolysis inhibition cascade. Finally, the lung colonization model validated that BA inhibited breast cancer metastasis in vivo, as well as suppressed the expression of aerobic glycolysis-related proteins. In conclusion, our study not only provided a promising drug for aerobic glycolysis inhibition but also revealed that GRP78 is a novel molecular link between glycolytic metabolism and ER stress during tumor metastasis.
- 1 April 2019
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 12 (7) , 691-692
Pulmonary Artery Denervation
- 1 April 2019
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 12 (7) , 691-692
Pulmonary Artery Denervation